Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model

Yonago Acta Medica - Japan
doi 10.33160/yam.2019.03.005
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Tottori University Faculty of Medicine

Related search

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin

Pharmaceutics
Pharmaceutical Science
2020English

In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2019English

Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ
2019English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Effects of Sodium Glucose Cotransporter Type 2 Inhibitors on Heart Failure

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes

Therapeutics and Clinical Risk Management
2018English

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy